Back

Pharma

2nd Annual Highly Potent Active Pharmaceutical Ingredients Summit

  • 3rd – 4th November 2016
  • Germany flag Germany Berlin
  • Crowne Plaza Berlin City Centre Nürnberger Str. 65, 10787

We are pleased to invite you to the “2nd Annual High Potency Active Pharma­ceutical Ingredients Summit” sched­uled on November 3rd - 4th, 2016 in Berlin.

Read more

About 

This premier B2B event will enable the participants to learn about the latest developments in the HPAPI Industry.

This Summit will be focusing on latest market devel­opment trends in the highly potent active pharmaceutical ingredients, global standards, innovation challenges & ex­pectations, sustainability, emerging markets, future trends & technological developments, outsourcing, etc.

It is an honor and privilege to invite you to participate in this Summit. We look forward to welcoming you at the Summit in Berlin upcoming November!

Who Should Attend

Chief Executives, Vice Presidents, Directors, Heads, Leaders, Senior Managers, Principal Scientists, Principal Toxicologists, Fellows and Investigators Specializing in:

  • Research & Development
  • Manufacturing
  • Risk Assessments
  • Laboratory Services
  • New Technologies
  • Process Development
  • Environmental, Health & Safety
  • Occupational Toxicology
  • Industrial Hygiene
  • New Products
  • Product Quality
  • Expertise
  • Innovations
  • Regulatory
  • Validation
  • Business Development
  • Partnerships and Alliances
  • Strategic Development
  • Sales Development
  • Formulation Development
  • External Supply
  • Outsourcing

Key Practical Learning Points

  • Strategies for the early development of linker-payloads for
    antibody-drug conjugates
  • Learn new containment life cycle
  • Discuss human operating at HPAPIs facility
  • Analyze the value proposition for validating exposure controls
    associated with the handling of APIs
  • See technical and operational challenges in developing highly
    potent cytotoxic agents in a biotech environment
  • Manufacturing considerations in the development of highly potent
    compounds – scale-ability & robustness addressing risks for the
    scale-up of highly potent compounds
  • Get to know leading professionals during interactive sessions
  • Learn proactive integration of occupational toxicology assessments
    into the drug development process planning

Justin Mason-Home, FRSC, UK

Director

HPAPI Project Services Limited

Justin Mason-Home is an organic chemist with extensive health, safety, environmental, and chemical engineering experience in senior technical, legal, and commercial aspects of the pharmaceutical, biochemical, chemical, and other industries. He is a Fellow of the Royal Society of Chemistry in the United Kingdom.

Justin started as a research chemist in the flavour and fragrance sector, researching and discovering new chemical synthetic routes to produce nature-identical flavour and fragrance components. In the fine chemical sector, he worked through scale-up (Kilo Lab then Pilot Plant) to full-scale manufacture. After a move to corporate environmental management, Justin was head-hunted into environmental consulting, heading a technical environmental engineering function.

He has since held senior positions and worked globally in potent biopharmaceutical occupational health and safety global environmental consulting, he's held a board level position in a biotechnology company, and has worked in corporate environmental management. Justin has been involved in and worked on potent and highly-potent API projects for more than 22 years and specialises in technical complex and strategic projects, including unique experience in managing sensitive highly-potent and toxic biopharmaceutical compound matters. Justin has chaired, presented at, and attended many HPAPI events and is a recognised expert in this area.

Richard Denk, CH

Head of Containment Group

Skan AG, Switzerland

Richard Denk has studied mechanical engineering and did an examination on experts of GMP, qualification and validation, pharmaceutical auditing, pharmaceutical engineering and quality control at the Albstadt-Sigmaringen University of Applied Sciences in Germany. Richard works at SKAN AG, headquartered in Allschwil, as the head of sales containment. Eight years ago he founded the expert containment group of the ISPE D/A/CH, and in 2015 they published the Containment Manual. Richard has spent nearly 20 years with the production of highly active and highly hazardous substances and has developed the containment pyramid.

Dr. Martin Guinn

Director of Chemical R&D & Consultant

Pfizer Inc., USA

Dr. Martin Butschies

Head of Laboratory Process Development Chemicals

Boehringer Ingelheim  Pharma GmbH & Co. KG, Germany

Dr. Jochen Becker

Senior Project Manager

Evonik Nutrition & Care GmbH, Germany

Eng. Stefano Butti

Head of Sales Group

Food Pharma Systems srl, Italy

Dr. Graham Box

Senior Programme Manager

Fujifilm Diosynth Biotechnologies, UK

Dr. Ester Lovsin, MscTox, ERT

Head Health Hazard Assessment Center of Excellence (HHA CoE)

Novartis HSE & BCM, Switzerland

Dr. Cynthia Wooge

Head of Process & Technology APIs, Excipients, & Cell Media Technology Cluster

Merck KGaA, USA

Jeffrey Dinyer, CIH, ROH

Director, Corporate Health & Safety

Patheon Inc., Canada

Dr. Scott A. Miller

Senior Scientific Advisor

CARBOGEN AMCIS AG, Switzerland

TIM BRIGGS

Programme Leader for the MSc OSH and BSc Safety Health & Environmental Management

Leeds Beckett University

Tim is a Chartered Fellow of IOSH and is currently employed by Leeds Beckett University as the course leader for the MSc Occupational Safety and Health the BSc Honours degree in Safety, Health and Environment Management. He has been the lead academic in developing the Fran­chise Arrangement for MDIS in Singapore. He is a Past President of the Institution of Occupational Safety and Health, and has been instrumental in driving forward a scheme of mentoring among the health and safety profession. Currently he is the Chair of the IOSH Professional Standards Committee. His Masters Degree in Training and Development has pro­vided the foundations for his research interests and published papers that encompass improving leadership in classrooms and workplaces, as well as developing employee knowledge and skills. He has a varied range of work experiences including public transport, health, education and defence. He is a graduate of Huddersfield, Nottingham Trent University and Leeds Beckett University.

Justin Mason-Home, FRSC, UK

Director

HPAPI Project Services Limited

Richard Denk, CH

Head of Containment Group

Skan AG, Switzerland

Dr. Martin Guinn

Director of Chemical R&D & Consultant

Pfizer Inc., USA

Dr. Martin Butschies

Head of Laboratory Process Development Chemicals

Boehringer Ingelheim  Pharma GmbH & Co. KG, Germany

Dr. Jochen Becker

Senior Project Manager

Evonik Nutrition & Care GmbH, Germany

Eng. Stefano Butti

Head of Sales Group

Food Pharma Systems srl, Italy

Dr. Graham Box

Senior Programme Manager

Fujifilm Diosynth Biotechnologies, UK

Dr. Ester Lovsin, MscTox, ERT

Head Health Hazard Assessment Center of Excellence (HHA CoE)

Novartis HSE & BCM, Switzerland

Dr. Cynthia Wooge

Head of Process & Technology APIs, Excipients, & Cell Media Technology Cluster

Merck KGaA, USA

Jeffrey Dinyer, CIH, ROH

Director, Corporate Health & Safety

Patheon Inc., Canada

Dr. Scott A. Miller

Senior Scientific Advisor

CARBOGEN AMCIS AG, Switzerland

TIM BRIGGS

Programme Leader for the MSc OSH and BSc Safety Health & Environmental Management

Leeds Beckett University